Clinical trials · Massachusetts
Carcinoma clinical trials in Massachusetts
We’re tracking 239 recruiting carcinoma studies with a site in Massachusetts — including Phase 1, Phase 1/Phase 2, Phase 2, Phase 2/Phase 3 and Phase 3 studies, each written for real people, not researchers.
Recruiting studies in Massachusetts
- NCT05123482RecruitingPhase 1/Phase 2
Study of an experimental drug for advanced solid tumors
This trial tests a new drug, called AZD8205, alone or with other medicines, for people with advanced or metastatic solid tumors that have not responded to standard treatment. It aims to see if the drug can shrink tumors or slow their growth.
Boston, MassachusettsAges 18 years+ - NCT05096715RecruitingPhase 1
Testing atezolizumab plus bevacizumab with SBRT for advanced liver cancer
This Phase 1 trial tests how well a combination treatment works for liver cancer that cannot be removed with surgery or other local treatments. It combines two immune/targeted medicines with a focused type of radiation (SBRT) to control the tumors.
Boston, MassachusettsAges 18 years+ - NCT04997096Recruiting
Exercise during chemo to prevent weakness from low movement
This study tests whether a structured exercise program during chemotherapy can help prevent physical decline (“immobility,” like getting weaker or moving less) in people with certain ovarian or endometrial cancers. If you’re eligible, you may be guided to exercise while receiving standard chemo, and you’ll have blood tests to track changes.
Boston, MassachusettsAges 18 years+ - NCT04892173RecruitingPhase 3
Radiation plus a tumor injection, with or without cetuximab
This trial studies whether adding a special drug given directly into a head-and-neck tumor during radiation can improve outcomes. It also looks at whether cetuximab (an antibody medicine) should be added for people who cannot or should not have certain standard chemotherapy.
Boston, MassachusettsAges 60 years+ - NCT04879329RecruitingPhase 2
Study for HER2-positive bladder cancer after limited treatment
This Phase 2 trial tests disitamab vedotin alone or with pembrolizumab for urothelial (bladder/urinary tract) cancer that has HER2-positive tumors. It aims to shrink tumors and improve outcomes, including for people who have had limited prior treatment or specific prior drug exposures.
Worcester, MassachusettsAges 18 years+ - NCT04900818RecruitingPhase 1
Givastomig for advanced solid cancers, including gastric and pancreas
This Phase 1 trial tests how safe and effective givastomig (TJ033721) is for advanced or metastatic solid tumors. It may help people whose cancer has grown despite standard treatment, or—if in the combination parts—specific cancers that meet certain lab test and tumor-marker requirements.
Boston, MassachusettsAges 18 years+ - NCT04684368RecruitingPhase 2
New treatment for children and young adults with a brain tumor
This trial tests a new treatment approach for a rare brain tumor called NGGCT. It aims to see if a different way of treating the tumor can be effective and safe for children and young adults.
Boston, MassachusettsAges 3–29 - NCT04752722RecruitingPhase 1/Phase 2
Gene therapy for bladder cancer that came back after BCG
This study tests a new gene therapy (EG-70) given directly into the bladder for people with a high-risk bladder cancer called NMIBC. It may be an option if BCG treatment stopped working, or if you cannot have or choose not to have bladder removal surgery.
Boston, MassachusettsAges 18 years+ - NCT04628767RecruitingPhase 2/Phase 3
Durvalumab plus chemo before surgery for upper tract cancer
This trial tests whether adding an immunotherapy drug (durvalumab) to chemotherapy before surgery can improve outcomes for people with high-grade upper tract urothelial cancer. It compares different treatment approaches based on whether a patient can receive cisplatin chemotherapy.
Worcester, MassachusettsAges 18 years+ - NCT04620187RecruitingPhase 2
Study medicine T-DM1 after surgery for HER2-positive salivary cancer
This Phase 2 trial studies T-DM1 given after surgery for salivary gland cancer that is HER2-positive. The goal is to reduce the risk of the cancer coming back by targeting HER2-positive tumor cells.
Boston, MassachusettsAges 18 years+ - NCT04472338Recruiting
Prostate cancer screening for people with higher genetic risk
This study looks at prostate cancer screening for people who may be at higher risk because of a specific inherited (genetic) change. It may help your care team find the best screening approach to catch aggressive prostate cancer earlier.
Boston, MassachusettsAges 40 years+ - NCT04251052Recruiting
Compare two surgeries to lower ovarian cancer risk in BRCA1 carriers
This study compares two risk-reducing surgery plans for people with a BRCA1 genetic change to see which approach helps lower ovarian cancer risk. You may be asked to have the study procedure sooner or later depending on your chosen plan.
Springfield, MassachusettsAges 35–50 - NCT04165798Recruiting
Pembrolizumab with or without chemotherapy for stage IV lung cancer
This trial tests whether pembrolizumab alone, or pembrolizumab plus chemotherapy, can treat stage IV non-small cell lung cancer. It may help shrink tumors and improve outcomes by boosting the immune system, with or without added chemotherapy.
Boston, MassachusettsAges 18 years+ - NCT04165070RecruitingPhase 1/Phase 2
Stage IV lung cancer trial using pembrolizumab with or without chemotherapy
This Phase 1/2 study tests pembrolizumab (an immune-based cancer treatment) either alone or with chemotherapy in people newly diagnosed with stage IV non-small cell lung cancer (NSCLC). It looks at how well the treatments work and whether they are safe, especially in people who haven’t had treatment yet for metastatic disease.
Boston, MassachusettsAges 18 years+ - NCT04104776RecruitingPhase 1/Phase 2
Test drug tulmimetostat for advanced cancers and lymphomas
This early-phase study tests tulmimetostat (DZR123) to shrink or control advanced solid tumors and certain lymphomas, and it may also test a combination in some prostate cancer groups. If you qualify, you’ll receive the study drug and be monitored closely, including blood tests and a request for tumor tissue to look for biomarkers.
Boston, MassachusettsAges 18 years+ - NCT03972657RecruitingPhase 1/Phase 2
Testing a new prostate and kidney cancer drug with immunotherapy
This early trial tests whether REGN5678 (nezastomig) is safe and how well it works, either by itself or with an immunotherapy drug (cemiplimab). It targets adults with metastatic castration-resistant prostate cancer and certain metastatic kidney cancers that have already been treated.
Boston, MassachusettsAges 18 years+ - NCT03875716Recruiting
De-intensified radiation after surgery for HPV throat cancer
This trial studies a lower-intensity (less aggressive) course of radiation therapy after curative surgery for HPV-related tonsil or base-of-tongue cancer. The goal is to see if patients can still be treated successfully while reducing side effects from radiation.
Boston, MassachusettsAges 18 years+ - NCT03526835RecruitingPhase 1/Phase 2
Study of MCLA-158 for advanced solid tumors
This trial tests a new experimental drug called MCLA-158 (petosemtamab) for people with advanced solid tumors, especially head and neck cancer or colorectal cancer, that have not responded to standard treatments. The study aims to see if this drug can shrink tumors or slow their growth.
Boston, MassachusettsAges 18 years+ - NCT03448926Recruiting
DCIS test registry to guide radiation and drug decisions
This study collects information from people with breast ductal carcinoma in situ (DCIS) to see how a specific lab test (DCISionRT) may help predict who benefits from radiation and/or certain medications. Your results and clinical details are gathered during routine care, not necessarily to change treatment right away.
Boston, MassachusettsAges 30–85 - NCT02402244Recruiting
Caring registry study for children and young people with cancer
This study keeps a careful record of children, teens, and young adults with cancer (and some related growths) and may follow them over time. It helps researchers better track outcomes and future contact so care can improve.
Boston, MassachusettsAges Up to 25 years - NCT02610426Recruiting
Genetic testing to study who develops heart failure during breast cancer therapy
This study uses DNA genetic testing to find DNA changes that might explain why some people develop heart failure (CHF) after breast cancer treatment with certain medicines. It may help researchers understand risk and improve care for future patients.
Boston, MassachusettsAges Any age - NCT02610439Recruiting
Genetic testing to find causes of paclitaxel nerve damage
This study uses genetic tests on blood DNA to look for differences that may explain why some people develop nerve pain (peripheral neuropathy) from paclitaxel used for breast cancer. It compares people who got significant neuropathy during treatment with people who did not get neuropathy after completing paclitaxel.
Boston, MassachusettsAges Any age - NCT02610413Recruiting
DNA testing to explain who gets severe blood pressure with bevacizumab
This study uses whole exome DNA testing to look for inherited genetic differences that may explain why some people develop very high blood pressure from bevacizumab during breast cancer treatment. It compares people who did vs. did not develop severe bevacizumab-related hypertension.
Boston, MassachusettsAges Any age
Carcinoma trials by city in Massachusetts
Where these studies are running in Massachusetts
Institutions with a site for the recruiting carcinoma studies listed above.
- Dana-Farber Cancer Institute · 8 studies
- Eastern Cooperative Oncology Group · 3 studies
- Massachusetts General Hospital · 3 studies
- Massachusetts General Hospital Cancer Center · 3 studies
- Baystate Medical Center · 2 studies
- Beth Israel Deaconess Medical Center · 2 studies
- Brigham and Women's Hospital · 2 studies
- Dana Farber Cancer Institute ( Site 0002) · 2 studies
What taking part in a carcinoma study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
Carcinoma trials in other states
Common questions
- Are there carcinoma clinical trials in Massachusetts?
- Yes. We're currently tracking 239 recruiting carcinoma studies with a site in Massachusetts, each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a carcinoma study in Massachusetts?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in Massachusetts to take part?
- Not necessarily. These studies have a site in Massachusetts, but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a carcinoma trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New carcinoma studies open in Massachusetts regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.